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Streptomyces toyocaensis produces A47934,
a teicoplanin-like type-IV glycopeptide with
antibiotic activity against methicillin-resistant
Staphylococcus aureus. A47934 differs from
the type-I vancomycin glycopeptides, which
possess a tricyclic peptide backbone, by the
presence of an additional ring closure between
the aromatic amino acids 1 and 3. To elucidate
the order of crosslinking reactions, P450 mono-
oxygenase-inactivation mutants (DstaF,DstaG,
DstaH, andDstaJ) of the A47934 producer were
generated, and the accumulated intermediates
were analyzed. Thus, the formation of each
crosslink could unambiguously be assigned
to a specific oxygenase. The structure of the
released intermediates from the wild-type non-
ribosomal peptide synthetase assembly line
facilitated the determination of the cyclization
order. Unexpectedly, the additional ring closure
in A47934, catalyzed by StaG, is the second
oxygenase reaction.
INTRODUCTION
Since the discovery of vancomycin, produced by Amyco-
latopsis orientalis, in the 1950s the family of glycopeptide
antibiotics has grown to several hundred currently known
members [1]. Two representatives, vancomycin (1) and
teicoplanin (3) (Figure 1), have been approved for clini-
cal use and are indispensable as last-resort antibiotics
against severe infections with Gram-positive bacteria,
such as Enterococci and methicillin-resistant Staphylo-
coccus aureus (MRSA) strains. The basis for antibacterial
activity of glycopeptide antibiotics is the noncovalent
binding via five hydrogen bonds from the peptidic back-
bone to the D-alanyl-D-alanine peptidyl residues of cell
wall intermediates [2]. Thus, glycopeptide antibiotics are
substrate binders that shield the substrate from transpep-1078 Chemistry & Biology 14, 1078–1089, September 2007 ª2tidation steps in peptidoglycan assembly. However, over
the past 15 years, a considerable number of glycopep-
tide-resistant bacteria have emerged. Current efforts to
counteract these resistant strains include the exploration
of natural and synthetic sources because of their poten-
tial for producing future antibacterials. An alternative
approach is to rely on an established core structure and
to modulate this structure by synthetic, semisynthetic, or
biotechnological approaches (e.g., genetic engineering
and combinatorial biosynthesis [3]). A prerequisite to the
application of the latter is the understanding of the biosyn-
thetic assembly of glycopeptide antibiotics.
The common structural feature in all glycopeptide anti-
biotics is the heptapeptide backbone with aromatic amino
acids oxidatively coupled in the side chains via biaryl or
biarylether bridges (Figure 1). They force the peptide
backbone into a rigid conformation and thus confer the
primary antibiotic activity of this compound class. Linear
and various other monocyclic or bicyclic intermediates
have been found to have no antibacterial activity [4–8].
Further structural modifications of the heptapeptide agly-
con backbone consist of N-methylation, halogenation,
and the attachment of sugar and/or fatty acid moieties.
The biosynthetic assembly of these complex structures
may be considered to be tripartite, i.e., the supply of build-
ing blocks (unusual amino acids and carbohydrates), the
nonribosomal peptide synthetase (NRPS) assembly line,
and the modification reactions (e.g., glycosylation, meth-
ylation) [9, 10]. Previous gene-inactivation studies on
the vancomycin-type (type-I) glycopeptide antibiotic
balhimycin (2) have shown that three P450-dependent
mono-oxygenases, OxyA, OxyB, and OxyC (Figure 2),
are responsible for forming the three crosslinks between
the aromatic amino acid side chains [5, 6]. These are
performed in the following sequence: amino acids 4 and
6 (C-O-D ring), amino acids 2 and 4 (D-O-E ring), and
amino acids 5 and 7 (AB ring) [5–7]. Furthermore, it has
been suggested that these crosslinking reactions occur
on an NRPS-oxygenase complex [11, 12].
A characteristic feature of teicoplanin-type (type-IV) gly-
copeptide antibiotics is an additional side chain crosslink
between aromatic amino acids 1 and 3 (F-O-G ring) [13].007 Elsevier Ltd All rights reserved
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Glycopeptide Side Chain CyclizationFigure 1. Structures of the Type-I Glycopeptide Antibiotics Vancomycin, 1, and Balhimycin, 2, and of the Type-IV Glycopeptide
Antibiotics Teicoplanin, 3, and A47934, 4a
Framed sketches on the top reflect the structures of the peptide backbones with three and four rings (C-O-D, D-O-E, AB, and F-O-G), respectively.Considering the results obtained for the vancomycin-type
(type-I) glycopeptide system, this raises the question as to
whether or not an analogy exists between both systems
in the sequence of ring-formation reactions. We chose
A47934 (4a), produced by Streptomyces toyocaensis
NRRL 15009, as a model compound for type-IV glycopep-
tides [14]. The A47934 biosynthetic gene cluster includes
four genes (staF, staG, staH, and staJ) (Figure 2) whose
gene products show high sequence similarities to P450
mono-oxygenases. Analogous to the balhimycin model,
they have been predicted to catalyze the four ring closures
in the aromatic amino acids [15–17].
Here, we report the construction of nonpolar mutants in
each A47934 oxygenase gene and the structural charac-
terization of the synthesized intermediates by mass spec-
trometry. Constructed mutants were homologously and
heterologously complemented by using the oxygenase
genes from the A47934 producer and the oxygenase
genes from the vancomycin producer, respectively. Fi-
nally, peptides related to A47934 assembly were directly
identified in culture filtrates of the wild-type strain by
HPLC-ESI-MS. From these studies, we were able to assign
the function of the above-mentioned four P450 mono-Chemistry & Biology 14, 1078–108oxygenases to distinct biosynthetic steps in A47934
assembly and were able to suggest a likely sequence of
oxidative crosslinking reactions.
RESULTS
Inactivation of the Oxygenase Genes staF, staG,
staH, and staJ in Streptomyces toyocaensis
The balhimycin biosynthetic gene cluster contains three
contiguous oxygenase genes that were functionally as-
signed to the three side chain crosslinks of the balhimycin
molecule (Figure 1). Furthermore, a stepwise sequence of
the oxygenase reactions was found in the following order:
OxyB/ OxyA/ OxyC [6]. In contrast to type-I glyco-
peptides, the glycopeptide antibiotic A47934 possesses
four side chain crosslinks. Accordingly, from sequence
analyses of the A47934-producer strain, four genes
(staF, staG, staH, and staJ) were identified and predicted
to be responsible for the four oxidative couplings during
biosynthesis. Phylogenetic analysis of P450 mono-oxy-
genases of the balhimycin A47934 and other glycopeptide
producers showed pronounced sequential relationships,9, September 2007 ª2007 Elsevier Ltd All rights reserved 1079
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Glycopeptide Side Chain CyclizationFigure 2. Genetic Organization of the Oxygenase Genes in the A47934 and Balhimycin Biosynthetic Gene Clusteras shown in Figure 3. Subsequently, from these relation-
ships and the knowledge of balhimycin aglycon assembly,
distinct biosynthetic steps were deduced for the P450
mono-oxygenases. As a consequence, StaF (72% identi-
cal to OxyA, but no more than 39% identical to the other
Oxy proteins) was predicted to be involved in the cross-
linking of amino acids 2 and 4 (D-O-E ring), StaH (77%
identical to OxyB, but no more than 49% identical to the
other Oxy proteins) was predicted to be involved in the
crosslinking of amino acids 4 and 6 (C-O-D ring), and
StaJ (68% identical to OxyC, but no more than 50% iden-
tical to the other Oxy proteins) was predicted to be in-
volved in the crosslinking of amino acids 5 and 7 (AB
ring). Only StaG shows no significant identity to any of
the balhimycin oxygenases (no more than 44%); therefore,
it was hypothesized to catalyze the teicoplanin-specific
crosslink between amino acids 1 and 3 (F-O-G ring).
In-frame deletion mutants of all oxygenase genes were
constructed to functionally assign the four oxygenases,
StaF, StaG, StaH, and StaJ, to distinct biosynthetic steps.
The nonreplicative gene-inactivation plasmids, pBHstaF,
pBHstaG, pBHstaH, and pBHstaJ (for construction, see
Experimental Procedures), carrying the flanking regions
of the corresponding oxygenase gene were used for
transformation of the wild-type strain S. toyocaensis by
protoplast transformation. The selection was based on
the plasmid apramycin resistance marker and therefore
only those recombinants that had integrated the inactiva-
tion plasmids pBHstaF, pBHstaG, pBHstaH, or pBHstaJ
into the chromosome via homologous recombination be-
tween one of the cloned fragments and the corresponding
chromosomal gene region were able to grow. The pres-
ence of the plasmids was verified by PCR amplification1080 Chemistry & Biology 14, 1078–1089, September 2007 ª20of a fragment of the apramycin-resistance cassette (data
not shown). In order to select gene deletion mutants in
which a second homologous recombination event via
the second cloned fragment had occurred, the inactiva-
tion mutants were subjected to a ‘‘stress’’ treatment (see
Experimental Procedures). This protocol has been devel-
oped to increase the probability of a second crossover
event. After the application of this ‘‘stress’’ protocol,
900, 600, 5000, and 900 colonies for mutations in staF,
staG, staH, and staJ, respectively, were examined on R5
plates with and without apramycin. For staF 15, for staG
14, for staH 32 and for staJ eight colonies were identified
which had lost the plasmid as indicated by the lack of the
apramycin resistance. Subsequent PCR analyses con-
firmed the internal deletion of the oxygenase genes (Fig-
ure 4). As a result of this selection process, 6 DstaF, 1
DstaG, 13 DstaH, and 1 DstaJ mutant were identified as
in-frame deletion mutants. The B. subtilis bioassay
showed that these colonies were incapable of producing
A47934 (data not shown), confirming that, in those cases,
the second crossover had led to the exchange of the wild-
type allele for the deleted oxygenase genes, and not to the
reversion of clones to the wild-type.
Analyses of the Metabolite Spectrum of the
Deletion Mutants via HPLC-ESI-MS and -MS/MS
Based on previous studies of the balhimycin system [5, 6],
the chlorination of peptide metabolites was employed as
a suitable indicator for mass spectrometric detection of
glycopeptide metabolites (Figures 5 and 6). Culture fil-
trates of the wild-type that have been used as a reference
showed A47934 (M = 1311.1 Da) (4a) and the nonsulfated
analog (M = 1231.2 Da) (4b) as the main metabolites. The07 Elsevier Ltd All rights reserved
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Glycopeptide Side Chain CyclizationFigure 3. Phylogenetic Analyses of Oxygenase Proteins from Vancomycin-Type and Teicoplanin-Type Glycopeptides
Oxygenases with significant homologies are assigned to putative functions: the cyclization of the C-O-D, D-O-E, F-O-G, and AB rings.HPLC-ESI-MS analyses of all four oxygenase deletion
mutants indicated the absence of A47934 detected in
the culture filtrates of the S. toyocaensis wild-type. The
structural assignment of peptides from DstaF, DstaG,
DstaH, and DstaJ mutants had to be performed solely
based on MS/MS experiments since an isolation of milli-
gram amounts (e.g., for NMR experiments) was not possi-
ble due to a very low titer.
The DstaJ mutant produces only the tricyclic hexa- (9a,
9b) and heptapeptides (16a, 16b) (Figure 5), and the inter-
pretation of fragment spectra indicates the presence of
structures with C-O-D, F-O-G, and D-O-E rings. This im-
plies that StaJ catalyzes the AB ring formation. In the bal-
himycin system, the AB ring is the third, and concomitantly
the final, ring formed by OxyC. The sequential analogy of
StaJ and OxyC on a phylogenetic base (Figure 3) supports
the functional assignment deduced from the experimental
findings.
For the DstaF mutant, five metabolites were identified
(Figures 5 and 6). In addition to the main metabolite on
the hexapeptide level, a hexapeptide with two side chain
cyclizations (C-O-D and F-O-G ring) (8b), a monocyclic
hexapeptide (C-O-D) (6b), and a linear hexapeptide (5b)
were detected. On the heptapeptide level, we observed
two main metabolites with molecular masses correspond-
ing to a bicyclic (13b) and a tricyclic heptapeptide (15b).
The interpretation of the fragment spectra localized
the side chain cyclizations at the C-O-D/F-O-G andChemistry & Biology 14, 1078–108C-O-D/F-O-G/AB rings, respectively. The absence of the
D-O-E ring in DstaF mutant intermediates indicates that
StaF is responsible for D-O-E ring formation. In the balhi-
mycin producer, D-O-E ring formation is catalyzed by
OxyA as the second step of the oxygenase reactions,
which supports the validity of the assumption based on
the sequence analysis of OxyA and StaF (Figure 3). Re-
markably, StaJ is able to catalyze the AB cyclization on
the heptapeptide level regardless of the presence of the
D-O-E ring, which differs from the sequential ring assem-
bly in the balhimycin system.
In the culture filtrate of the DstaG mutant, molecular
masses that correlate to a monocyclic hexapeptide with
the C-O-D ring (6b) and a bicyclic heptapeptide (12b)
with C-O-D and AB crosslinks as main metabolites were
identified. The molecular masses of a linear (5b) and a bi-
cyclic hexapeptide (C-O-D/D-O-E) (7b) as well as of
a monocyclic (C-O-D) (11b) and a tricyclic heptapeptide
(14b) were detected, albeit in much lower concentrations.
Since 14b occurred only in traces, the crosslinking pattern
could not be unambiguously determined. However, the re-
tention time differs from other tricyclic heptapeptides, 15b
of DstaF (C-O-D, F-O-G, and AB) and 16b of DstaJ (C-O-D,
F-O-G, and D-O-E), which argues for the C-O-D/D-O-E/
AB ring combination as the only remaining possibility.
These data suggest that StaG is the mono-oxygenase
forming the F-O-G ring. This finding is supported by se-
quence analysis (Figure 3) which indicates a significant9, September 2007 ª2007 Elsevier Ltd All rights reserved 1081
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Glycopeptide Side Chain CyclizationFigure 4. PCR Analysis for Verification of
the In-Frame Mutation in staF
The in-frame mutation is representative of all of
the Dsta mutants. Marker, 1 kb ladder; lane 1,
2293 bp staF fragment with S. toyocaensis
wild-type DNA as template; lane 2, negative
control with H2Odeion. as template; lane 3,
1183 bp fragment with plasmid pBHstaF as
template; lane 4, 1183 bp fragment with
S. toyocaensis DstaF DNA as template. In all
cases, the primer pair prdelstaF1/F2 (arrows;
for the sequence, see Table S2) was used.lack of similarity to other mono-oxygenases of the van-
comycin system. Furthermore, the results suggest that
F-O-G ring formation is not a precondition for the ring
formation catalyzed by StaF, and that StaJ can catalyze
AB ring formation regardless of the cyclization pattern of
the molecule (as observed in the DstaF mutant).
Analysis of theDstaHmutant revealed a molecular mass
of 1239.4 Da (10b) and a mass shift of 8 atomic mass units
(amu) to higher masses, compared to the nonsulfated
wild-type metabolite (4b). This lack of all four side chain
cyclizations corresponds to a linear heptapeptide struc-
ture that was confirmed by MS/MS fragment spectra. An
additional metabolite of DstaH with a molecular mass of
1074.2 Da (5b) suggests a linear, nonsulfated, C-termi-
nally truncated hexapeptide. These findings confirm that
StaH catalyzes the first ring closure reaction of the peptide
cyclization sequence. This biosynthetic step is analogous
to the first oxygenase reaction (C-O-D) in the balhimycin
biosynthesis, which is catalyzed by OxyB.1082 Chemistry & Biology 14, 1078–1089, September 2007 ª20Identification of Biosynthetic Intermediates
in Culture Filtrates of the Wild-Type
Strain Streptomyces toyocaensis via
HPLC-ESI-MS and -MS/MS
In order to reveal information about the teicoplanin-type
glycopeptide biosynthesis, an alternative approach that
was independent of gene-inactivation experiments was
persued. Hence, culture filtrates of the A47934 wild-type
producer were screened for biosynthetic intermediates.
We predominantly used the characteristic isotope pattern
of chlorinated di- to heptapeptides as a marker for the
identification of these putative A47934 biosynthesis inter-
mediates. Furthermore, we considered tailoring reactions,
(e.g., sulfatation and oxidative side chain cyclization) to
be variables occurring at various points in time during or
after peptide assembly. HPLC-ESI-MS analyses were
performed as full-scan experiments that were searched
by the extracted ion chromatogram (EIC) mode for puta-
tive m/z values. As a result of this screening, molecular07 Elsevier Ltd All rights reserved
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Glycopeptide Side Chain CyclizationFigure 5. Synopsis of all Hexa- and Heptapeptides Detected in the Culture Filtrates of A47934 Mutants—DstaH, DstaG, DstaF and
DstaJ—and Wild-Type Characterized by HPLC-ESI-MS and -MS/MS
All metabolites are fully chlorinated. A semiquantitative estimation of metabolite synthesis was performed according to ionization yields (++ = main
metabolite; + = minor metabolite, < 10% total production). Metabolites designated with ‘‘a’’ are sulfated; those designated with ‘‘b’’ are nonsulfated
([M+H]+ in brackets). [M+H]+ values have been calculated from the molecular formula.masses of C-terminally truncated peptides corresponding
to hypothetically calculated di-, tri-, tetra-, penta-, hexa-,
and heptapeptides were detected. A more detailed and
specific analysis with HPLC-ESI-MS/MS daughter ion
scans yielded characteristic fragment spectra, which
were assigned to the peptides related to A47934. The in-
terpretation of analytic data by using a combination of mo-
lecular masses and fragment spectra resulted in a set of
compounds depicted in Figure 5 (dipeptides-pentapep-
tides data not shown).
Out of these compounds, the dipeptides to pentapep-
tides are all linear. Among the hexapeptides, four deriva-Chemistry & Biology 14, 1078–1089tives, corresponding to different degrees of cyclization,
were detected. Interpretation of daughter ion experiments
revealed a linear hexapeptide (5b), a monocyclic hexa-
peptide (6b) with a C-O-D ring, and a bicyclic hexapeptide
(8a, 8b) with C-O-D and F-O-G rings. Based on the frag-
ment spectra of the tricyclic hexapeptide (9a, 9b), there
remains only one possibility for the assignment of the
structures with the C-O-D, F-O-G, and D-O-E rings. On
the heptapeptide level, only the tetracyclic peptides
were observed (4a, 4b). With regard to sulfation, only the
bi- and tricyclic hexapeptides and the tetracyclic hepta-
peptide were found to have been modified., September 2007 ª2007 Elsevier Ltd All rights reserved 1083
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Glycopeptide Side Chain CyclizationComplementation of the Deletion Mutants DstaF,
DstaG, DstaH, and DstaJ with the A47934 and the
Corresponding Vancomycin Oxygenases
Complementation experiments were performed to ex-
clude the polar effects of the genetic manipulations in
the oxygenase mutants DstaF, DstaG, DstaH, and DstaJ.
We could show, via agar diffusion assays for antibacterial
activity (data not shown) and HPLC-ESI-MS, that the in-
sertion of the respective plasmids, pSETstaF, pSETstaG,
pSETstaH, and pSETstaJ (containing the A47934 oxygen-
ase genes under the control of the constitutive promoter
PermE), at the FC31 attachment site (attB) could fully
complement the mutants and thus reconstitute A47934
synthesis.
Crosscomplementation experiments were performed
to confirm the functional relationship between A47934
oxygenase genes and the corresponding genes from pro-
ducers of vancomycin-like glycopeptides that was
deduced from in situ sequence analysis (Figure 3). Be-
cause of the predicted functional equivalence between
the balhimycin and the vancomycin oxygenases and be-
cause of the availability of the expression plasmids pSET-
vanoxyA, pSETvanoxyB, and pSETvanoxyC [7] containing
the vancomycin oxygenase genes, which are under the
control of the constitutive promoter PermE, we used
them for crosscomplementation experiments. As pre-
dicted, we were able to complement the DstaH mutant
with only the corresponding vanoxyB gene, and the DstaJ
mutant with only the corresponding vanoxyC gene. In both
cases, the production of active A47934 was restored. Al-
though VanoxyA shows the highest identity to StaF, no
complementation was achieved, nor was complementa-
tion possible with the other vancomycin oxygenase
genes. StaG is unique because it shows no significant
identity to any of the balhimycin, or rather vancomycin,
oxygenase genes. As expected, no complementation of
the DstaG mutant was possible.
DISCUSSION
In recent studies, the side chain crosslinking reactions
performed by P450-type mono-oxygenases were exten-
sively investigated to determine the biosynthesis of the
vancomycin-type glycopeptide balhimycin. Each of the
three balhimycin oxygenase genes (oxyA–C), identified in
the balhimycin biosynthesis gene cluster, is correlated to
one of the three side chain cyclizations, for which a strict
sequence has been determined (OxyB / OxyA /
OxyC) [6]. Analogous to this approach, we utilized this
gene-inactivation strategy to gain insights into the oxy-
genase reactions of the four-fold, side chain-cyclizedChemistry & Biology 14, 1078–1089,teicoplanin-type glycopeptide A47934. The previously
proposed oxygenase genes for the aglycon assembly of
A47934 staF, staG, staH, and staJ [15] were inactivated
by the generation of deletion mutants. The subsequent
HPLC-ESI-MS analysis of culture filtrates of these mu-
tants (DstaF, DstaG, DstaH, and DstaJ) revealed peptides
with different degrees of cyclization (Figure 5). The loca-
tion of the rings in the peptide backbones of mutant me-
tabolites was determined via the assignment of fragments
from MS/MS experiments. From the mass spectrometric
data obtained for all mutants, we can deduce and assign
enzyme functions to each of the four P450-type mono-
oxygenases: StaF, StaG, StaH, and StaJ.
From the DstaH mutant, only linear metabolites (5b,
10b) were detected. Based on the findings from the balhi-
mycin model [11], StaH would perform the first ring-clo-
sure reaction, which involves the C-O-D ring. This is in
full accordance with the similarity of OxyB and StaH based
on phylogenetic data. Furthermore, the mass spectromet-
ric analyses imply that the subsequent action of other oxy-
genases is blocked if the first ring closure has not been
catalyzed, since no other cyclic derivatives were found.
In the cultural filtrates of the DstaJ mutant, only the
tricyclic peptides (9a, 9b and 16a, 16b) were detected.
Because mass spectrometric data only showed the
C-O-D, F-O-G, and D-O-E rings, we can clearly assume
that StaJ oxygenase catalyzes AB ring formation. The
finding of the tricyclic heptapeptide (15b), synthesized
by the DstaF mutant, with C-O-D, F-O-G, and AB rings
assigns StaF to D-O-E ring formation. The fact that, in
addition to 15b, significant amounts of metabolites 5b,
6b, 8b, and 13b were detected, however, leads to further
assumptions about ring formation by oxygenases of the
A47934 biosynthesis gene cluster. For example, StaJ
can catalyze AB ring formation even if the D-O-E-ring syn-
thesized by StaF is missing.
The DstaG mutant predominantly synthesizes a mono-
cyclic (C-O-D) hexapeptide (6b) and a bicyclic (C-O-D,
AB) heptapeptide (12b). In accordance with the above-
mentioned finding for the DstaF mutant, this shows that
StaJ can also act on a monocyclic heptapeptide to cata-
lyze AB ring formation. Furthermore, some minor meta-
bolites, in particular (14b) a tricyclic heptapeptide, were
detected, which suggests that StaG is responsible for
the F-O-G ring. Together with the results obtained for the
DstaF mutant, these data show that StaJ can catalyze
the formation of the AB ring on the heptapeptide level, re-
gardless of the cyclization status of the other amino acid
residues, if the C-O-D ring is present. As previously men-
tioned, the results from the gene-inactivation experiments
suggest that StaH catalyzes the first ring closure (C-O-D)Figure 6. Representative Mass Spectrometric Analysis of Metabolites Detected in the Culture Filtrates of the DstaF Mutant
(A) Experimentally determined molecular masses and characteristic isotope patterns of metabolites. Mass shifts indicate structural differences
between the compounds.
(B) Assignment of fragment spectra from MS/MS experiments to various peptide structures. (The designation of the fragment ions arising from
cleavage sites along the peptide backbone is in accordance with the nomenclature of Roepstorff and Fohlman [29]. Secondary fragmentation events
occurring at phenolic hydroxy groups lead to [M+H-OH]+ and the corresponding fragment ions [F-OH]+.)September 2007 ª2007 Elsevier Ltd All rights reserved 1085
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quence are less obvious. StaG catalyzes the F-O-G cycli-
zation step; however, if StaG is nonfunctional, D-O-E ring
formation (catalyzed by StaF) can still occur. Finally, StaJ
catalyzes the cyclization (AB) on the heptapeptide back-
bone. Further confirmation of the assignment of
oxygenase functions came from complementation ex-
periments. All oxygenase genes could be homologously
complemented by the respective Sta oxygenase gene,
and thus formation of A47934 production could be re-
stored. In addition, crosscomplementation experiments
were performed with P450 mono-oxygenases, from
type-I glycopeptide producers, based on the sequential
similarity of oxygenases in the vancomycin producer. Re-
markably, a successful complementation was achieved
for the DstaH mutant with the most similar oxygenase,
vanoxyB (C-O-D), and for the DstaJ mutant with vanoxyC
(AB). No functional reconstitution was obtained upon
complementation of the DstaF mutant with vanoxyA, al-
though both proteins have an identity of 69% and the
functionality of the complementation construct containing
the vanoxyA gene has already been shown [7]. Because
DstaF catalyzes the formation of the F-O-G ring, which
is absent in vancomycin-type glycopeptides, VanoxyA
might not be capable of recognizing F-O-G ring-contain-
ing peptides as substrates. Despite a considerable se-
quential homology between StaF and VanoxyA, the action
of VanoxyA may be too specific for the recognition of
peptide intermediates from A47934. In contrast, the sub-
strates of OxyC and StaJ also differ in the presence of
the F-O-G ring, which does not affect the functional equiv-
alence of these enzymes.
Although we were able to assign oxygenase functions
to distinct catalytic reactions, based on gene inactivation
experiments, no unambiguous sequence for the oxidative
steps could be deduced. The findings for the oxygenases
of the A47934 biosynthetic gene cluster of S. toyocaensis
rather imply a skipping of some of the oxidative bio-
synthetic steps, as found for bicyclic and tricyclic pep-
tides synthesized by DstaG and DstaF. Therefore, we
speculated that this substrate flexibility of the oxygenases
may also exist in the wild-type. In order to clarify
whether a preferred sequence in side chain crosslinking
exists or whether a randomized action of StaF and StaJ
occurs, a second complementary approach was ex-
plored.
Previous observations, by other groups [18, 19], have
shown that biosynthetic intermediates found in minute
amounts in culture filtrates of wild-type antibiotic pro-
ducers can give insight into the biosynthesis of natural
products. We transferred this approach to peptide metab-
olites of the glycopeptide type. In wild-type fermentations
of S. toyocaensis, various peptide intermediates that have
been assigned to A47934 biosynthesis were detected
(Figure 5). The detected di- to pentapeptides are all linear
(data not shown), which suggests that the first oxidative
crosslink performed by StaH occurs at the hexapeptide
stage. With the exception of the tetracyclic heptapeptide
aglycon (4a, 4b), all other detected peptides in wild-type1086 Chemistry & Biology 14, 1078–1089, September 2007 ª20fermentations were hexapeptides. Among the four hexa-
peptide derivatives, the complete set was found ranging
from a linear (5b), to a monocyclic (6b), to a bicyclic (8a,
8b), and to a tricyclic (9a, 9b) derivative. These derivatives
were of defined structure (i.e., only one ring-closure pat-
tern was detected, and derivatives displaying alternative
ring structures were not found). In contrast to the skipping
or randomization of crosslinking steps, observed for the
gene-inactivation mutants DstaG and DstaF, the results
from the analysis of wild-type cultures suggest that there
is a preferred sequence for oxidative ring-closure reac-
tions. This sequence is as follows: C-O-D ring/ F-O-G
ring/ D-O-E ring/ AB ring, where StaH, StaG, StaF,
and StaJ are the corresponding catalysts. While the results
obtained for the wild-type indicate a defined sequence,
the intermediates in the culture filtrates of the deletion
mutants indicate oxygenase reactions of lowered spe-
cificity. Obviously, StaF and StaJ represent oxygenases
of decreased substrate specificity, which becomes appar-
ent in the deletion mutants, possibly because of the ac-
cumulation of intermediates only present in the deletion
mutants.
A common feature of the biosyntheses of type-I and
type-IV glycopeptide antibiotics is that the ring systems
are synthesized by the oxygenases at a time point not ear-
lier than the hexapeptide stage. In both glycopeptide sys-
tems, the C-O-D ring is consistently the first ring to be
closed, and no skipping of this reaction with subsequent
oxidative steps is allowed. The second oxidative step in
A47934 assembly is the formation of the F-O-G ring.
This biosynthetic step is followed by the formation of the
D-O-E ring and the AB ring, with both corresponding to
the sequence found for the assembly of the balhimycin
aglycon. This finding seems remarkable since the F-O-G
system does not necessarily contribute to the antibiotic
activity. Type-II glycopeptide (actinoidin) antibiotics with
aromatic amino acids in positions 1 and 3 lack the
F-O-G ring but still show antibiotic activity. Therefore, in-
tuitively one would have expected that the F-O-G ring is
the last ring formed and that it represents an ‘‘optional,’’
less-controlled step.
In summary, the oxidative crosslink assembly found in
the balhimycin system [6] is also observed in the A47934
wild-type. The mass spectrometric data imply an order
of the cyclization steps (StaH, then StaG, StaF, and
StaJ). However, in contrast to the balhimycin system,
the A47934 oxygenases exhibit flexibility if the substrate
supply is modified, as observed for the A47934 oxygenase
mutants DstaG and DstaF.
With regard to the assembly of A47934, we also assume
a close interaction of NRPS and oxygenases in a protein-
protein complex, as has previously been proposed [11,
12]. In this context, it has been shown with PCP-bound
linear hexa- and heptapeptides of the vancomycin bio-
synthesis that these are suitable substrates of OxyB [12].
The presence of cyclized hexapeptides in the gene-
inactivation mutants and the wild-type strain correlates
with this model and extends its validity to teicoplanin-
type glycopeptides.07 Elsevier Ltd All rights reserved
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The P450-type mono-oxygenases StaF, StaG, StaH,
and StaJ of the A47934-producer S. toyocaensis
have the capacity to crosslink linear precursor pep-
tides to form a tetracyclic antibiotic scaffold. This
scaffold is not only a characteristic structural feature
of glycopeptide antibiotics, but it is also the base for
antibiotic activity. By means of gene inactivation,
a precise correlation between the position of a biaryl-
or biarylether crosslink in the peptide backbone and
its catalyzing oxygenase was elaborated. Unlike with
the vancomycin-type glycopeptide balhimycin, the
gene-inactivation studies show a relaxed substrate
specificity of the Sta oxygenases. Only the combina-
tion of the mass spectrometric analysis of both the
gene-inactivation mutants and the wild-type cultures
allows for a functional assignment and deduction of
a biosynthetic sequence for oxygenase steps. This ap-
proach underlines the potential of HPLC-ESI-MS of
wild-type cultures as a predictive tool for biosynthetic
pathways, particularly for peptidic secondarymetabo-
lites, and points to the problem that investigations
with putative intermediates and purified enzymes
may indicate the occurrence of biosynthetic reactions
that only take place under artificial conditions. This
study increases the understanding of glycopeptide
biosyntheses and is considered to be a representative
example for type-IV glycopeptide antibiotics. Detailed
knowledge of biosynthetic pathways is the prerequi-
site for combinatorial biosynthesis that may serve as
a tool for the generation of novel antibiotics.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Plasmids
Escherichia coli XL1-blue [20] was used for cloning purposes, and the
methylation-deficient strain E. coli JM110 was used to obtain unme-
thylated DNA for Streptomyces transformations.
Streptomyces toyocaensis NRRL15009 is the A47934-producing
wild-type and was used to generate the oxygenase mutants BHstaF,
BHstaG, BHstaH, and BHstaJ (this study).
The inactivation plasmids pBHstaF, pBHstaG, pBHstaH, and
pBHstaJ are derivatives of the nonreplicative vector pA18mob (Table
S1, see the Supplemental Data available with this article online). The
vector pA18mob was constructed for the generation of insertion and
gene replacement plasmids. pA18mob derives from the vector
pK18mob [21] and contains an oriT and an apramycin-resistance
cassette from the plasmid pSET152 [22] instead of the kanamycin
cassette.
The integrative expression vector pSETermEp* [7] was used for the
complementation experiments.
Media and Culture Conditions
E. coli strains were grown in Luria broth (LB) medium [23] at 37C and
were supplemented with 100 mg ml1 apramycin when necessary to
maintain plasmids.
Liquid cultures of S. toyocaensis were cultivated in 100 ml R5
medium in an orbital shaker (180 rpm) in 500 ml Erlenmeyer flasks
with steel springs at 30C. Liquid/solid media were supplemented
with 50 mg ml1 apramycin to select for strains carrying integrated
antibiotic-resistance genes.Chemistry & Biology 14, 1078–1089Cloning, Restriction Mapping, and In Vitro Manipulation
of DNA
Methods for isolation and manipulation of DNA were described by
Sambrook et al. [24] and Kieser et al. [25]. PCR fragments were iso-
lated from agarose gels with QIAquick (QIAGEN, Hilden, Germany).
Restriction nucleases were purchased from various suppliers and
used according to their specifications. Transformation of E. coli was
performed by using the CaCl2 method described in Sambrook et al.
[24]. E. coli XL1-blue was used for standard cloning experiments.
Construction of the Inactivation Plasmids pBHstaF, pBHstaG,
pBHstaH, and pBHstaJ
Plasmids were constructed for the in-frame deletion of the individual
oxygenase genes.
All PCR protocols that were followed are included in the Supplemen-
tal Data.
For the deletion of staF, a 1965 bp upstream (frstaF1) and a 1954 bp
downstream fragment (frstaF2) of staF were amplified by PCR with the
primers prstaF1.1/prstaF1.2 and prstaF2.1/prstaF2.2, respectively.
The frstaF1 fragment consists of part of the staD gene and the com-
plete staE gene. The fragment frstaF2 consists of the complete staG
gene and part of the staH gene. The primers are equipped with syn-
thetic restriction sites at the 30 and 50 ends (EcoRI/XbaI and XbaI/
HindIII). Both fragments were cloned into the vector pA18mob, result-
ing in the plasmid pBHstaF.
The cloning of the plasmids pBHstaG, pBHstaH, and pBHstaJ fol-
lows the same strategy as that described for the cloning of plasmid
pBHstaF. The corresponding primers are equipped with the same
synthetic restriction sites.
The flanking regions of staG were amplified by PCR with the primers
prstaG1.1/prstaG1.2 and prstaG2.1/prstaG2.2, resulting in a 2010 bp
fragment, which consists of part of the staD gene and the complete
staE and staF genes, and a 2092 bp fragment, which encodes for
the staH gene and part of the staI gene, respectively. The fragments
were cloned into the vector pA18mob, resulting in the plasmid
pBHstaG.
For the inactivation of staH, a 2038 bp and a 2031 bp fragment were
amplified by PCR with the primers prstaH1.1/prstaH1.2 and prstaH2.1/
prstaH2.2, respectively. The fragment frstaH1 consists of the complete
staG gene and part of the staF gene, and frstaH2 encodes for the com-
plete staI gene and part of the staJ gene. Both fragments were cloned
into the pA18mob, resulting in the plasmid pBHstaH.
The inactivation plasmid pBHstaJ contains the flanking fragments of
staJ with a size of 2093 bp, which consist of staI and part of staH, and
a fragment of 1950 bp, which encodes staK and part of staL. The frag-
ments were amplified by PCR with the primers prstaJ1.1/prstaJ1.2 and
prstaJ2.1/prstaJ2.2, respectively.
Construction of the Complementation Plasmids pSETstaF,
pSETstaG, pSETstaH, and pSETstaJ
The expression plasmids pSETstaF, pSETstaG, pSETstaH, and pSET-
staJ were constructed for the complementation of the oxygenase
mutants.
All PCR protocols that were followed are included in the Supplemen-
tal Data.
The primers prcostaF1/2 were used to amplify the complete staF
gene from genomic DNA of S. toyocaensis with a synthetic ribosome
binding site (GGAGG) typical for Streptomyces, and the start and
stop codon of the gene, respectively. The primer prcostaF1 carries
a HindIII at the 50 end, and prcostaF2 carries an XbaI synthetic restric-
tion site at the 30 end. The amplified fragment of 1211 bp was cloned
into the vector pSETermEp* [7], which contains the strong constitutive
PermE* promoter, resulting in the plasmid pSETstaF.
The cloning of the plasmids pSETstaH and pSETstaJ follows the
same cloning strategy as for pSETstaF. For staH and staJ, 1232 and
1213 bp fragments, respectively, were amplified and cloned into
pSETermEp* (Table S1)., September 2007 ª2007 Elsevier Ltd All rights reserved 1087
Chemistry & Biology
Glycopeptide Side Chain CyclizationThe primers prcostaG1/2 carry a HindIII and a BamHI synthetic re-
striction site, respectively, as well as a synthetic ribosome-binding
site (50-GGAGG-30). The amplified fragment, consisting of the com-
plete staG gene with start and stop codons, of 1190 bp was cloned
into pSETermEp*, resulting in pSETstaG.
Protoplast Transformation of S. toyocaensis
The transformation of S. toyocaensis was carried out as described
by Matsushima and Baltz [26]. The cells were overlayed with top
agar to a final apramycin concentration ranging from 25 mg ml1 to
100 mg ml1.
‘Stress’ Treatment for Increasing the Frequency of Crossover
Events in S. toyocaensis
For increasing the frequency of crossover events in S. toyocaensis, the
‘‘stress’’ treatment described by Puk et al. [27] was modified. Cells
were first grown in 50 ml R5 medium for 24 hr at 30C, and then for
an additional 24 hr at 37C. For fragmentation, the mycelium was ultra-
sound treated as described. To obtain single colonies, protoplasts
were prepared as described by Matsushima and Baltz [26].
Qualitative Determination of A47934 Production by Bioassay
A47934 production was determined by bioassays with Bacillus subtilis
ATCC 6633 as the test organism [28], and cell supernatants of S. toyo-
caensis were grown in R5 medium.
HPLC-ESI-MS and -MS/MS
Investigations of the A47934 variants and precursors in the culture
broths of the wild-type and mutant strains were performed via
HPLC-ESI-MS and -MS/MS analyses. Culture broths were prepared
by centrifugation and filtration to obtain particle-free samples. To
optimize and facilitate the filtration of the supernatant, celite (Hyflo
Super-Cel, Haeffner, Asperg, Germany) was added. In order to allow
the detection of low-concentrated metabolites, particularly the bio-
synthetic intermediates of the wild-type cultures, several sample
preparation procedures were tested. In all cases, an adsorption chro-
matography with AMBERLITE XAD16 and XAD1180 material was per-
formed to remove large amounts of saccharose that had been added
to the culture media. In subsequent steps, solid-phase extraction
(bond elut C18, Varian, Darmstadt, Germany) as well as preparative
HPLC were performed. The resulting fractions were analyzed by
means of HPLC-ESI-MS and -MS/MS.
The HPLC-ESI-MS/MS system that was used consisted of a capil-
lary-LC system (1100 series, Agilent Technologies Deutschland
GmbH, Bo¨blingen, Germany) coupled to a QTrap2000 with a TurboIon-
Spray source (Applied Biosystems, Darmstadt, Germany). Separa-
tions were performed on a Jupiter 4u Proteo 90A column system
(main column, 150 3 1 mm; precolumn, 30 31 mm; Phenomenex,
Aschaffenburg, Germany) with a flow rate of 50 ml min1 in micro
mode and the following gradient: t = 0 min, 5% B; t = 10 min, 20%
B; t = 13 min, 50% B; t = 14 min, 100% B (solvent A: 0.1% HCOOH
in water; solvent B: 0.1% HCOOH in acetonitrile). The injection volume
was 5 ml. The TurboIonSpray source-dependent parameters were op-
timized for the flow rate of 50 ml min1 to: CUR, 30; IS, 5500; nebulizer
gas, 70; turbo gas, 70; TEM, 300. The compound-dependent parame-
ters were optimized with different glycopeptide derivatives described
previously [5, 6] to: DP, 30; EP, 12; CE, 10; Q3 entry barrier, 12. The
EMS scans were carried out in positive mode, with a LIT scan rate of
1000 amu/s and dynamic fill time. The daughter ion scans had the
following parameters: Q1 resolution unit; LIT scan rate, 1000 amu/s;
fixed LIT fill time, 500 ms; CAD gas, high. In order to prevent secondary
fragmentation, the most daughter ion scans were performed in
time-delayed fragmentation (TDF) mode and with different collision
energies.
Supplemental Data
Supplemental Data include all the PCR protocols, a table containing
bacterial strains and plasmids, and a table containing the used oligo-1088 Chemistry & Biology 14, 1078–1089, September 2007 ª2nucleotides, and are available at http://www.chembiol.com/cgi/
content/full/14/9/1078/DC1/.
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